Keeping Track: US FDA Receives Advanced Biologic BLAs From ImmunityBio, CSL; Nymox, Medac Stumble
Executive Summary
The latest NDA and BLA submission news and highlights from the Pink Sheet’s US FDA Performance Tracker
You may also be interested in...
Sanofi/Sobi’s Next-Gen Factor VIII Therapy BLA Heats Up Biotech-Driven Hemophilia Arms Race
Sanofi/Sobi’s efanesoctocog is in line for US FDA action three months after CSL/uniQure’s gene therapy user fee goal, while BioMarin’s Roctavian resubmission and Novo Nordisk’s concizumab are waiting in the wings.
Hemophilia Gene Therapies Should Have REMS For Approval, National Hemophilia Foundation Says
Agency should require physician training, facility certification, and patient registry as a condition for approving BioMarin's and CSL Behring’s investigational gene therapies, the advocacy group says. It calls for treatment to be limited to the population studied with no-off label use.
Keeping Track: TGT’s Ukoniq Is Latest PI3K Inhibitor To Fall; GSK’s Daprodustat, Aeglea’s Pegzilarginase Headline Submissions
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker